Inogen (NASDAQ:INGN) Stock Price Crosses Above 200-Day Moving Average – Should You Sell?

Inogen, Inc. (NASDAQ:INGN)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.23 and traded as high as $11.07. Inogen shares last traded at $10.64, with a volume of 340,965 shares traded.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on INGN. StockNews.com upgraded shares of Inogen from a “hold” rating to a “buy” rating in a research report on Monday, February 10th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Thursday, January 30th.

Inogen Price Performance

The firm has a market capitalization of $253.42 million, a P/E ratio of -4.73 and a beta of 1.02. The firm’s 50 day simple moving average is $10.07 and its two-hundred day simple moving average is $10.23.

Institutional Trading of Inogen

Several hedge funds have recently added to or reduced their stakes in INGN. Royce & Associates LP lifted its stake in Inogen by 167.4% in the third quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company’s stock worth $503,000 after purchasing an additional 32,482 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Inogen by 312.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after acquiring an additional 132,287 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Inogen by 13.9% during the third quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock valued at $409,000 after acquiring an additional 5,131 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Inogen during the third quarter valued at about $106,000. Finally, Paloma Partners Management Co bought a new position in shares of Inogen during the third quarter valued at about $126,000. 89.94% of the stock is owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.